- Home
- MSGY vs CHRS Comparison
MSGY vs CHRS Comparison
Compare MSGY & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSGY
- CHRS
- Stock Information
- Founded
- MSGY 2018
- CHRS 2010
- Country
- MSGY Hong Kong
- CHRS United States
- Employees
- MSGY N/A
- CHRS N/A
- Industry
- MSGY
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSGY
- CHRS Health Care
- Exchange
- MSGY Nasdaq
- CHRS Nasdaq
- Market Cap
- MSGY 186.3M
- CHRS 159.2M
- IPO Year
- MSGY 2025
- CHRS 2014
- Fundamental
- Price
- MSGY $2.51
- CHRS $1.64
- Analyst Decision
- MSGY
- CHRS Strong Buy
- Analyst Count
- MSGY 0
- CHRS 4
- Target Price
- MSGY N/A
- CHRS $4.51
- AVG Volume (30 Days)
- MSGY 775.8K
- CHRS 1.2M
- Earning Date
- MSGY 01-01-0001
- CHRS 11-05-2025
- Dividend Yield
- MSGY N/A
- CHRS N/A
- EPS Growth
- MSGY N/A
- CHRS N/A
- EPS
- MSGY 0.10
- CHRS 1.55
- Revenue
- MSGY $23,318,482.00
- CHRS $272,209,000.00
- Revenue This Year
- MSGY N/A
- CHRS N/A
- Revenue Next Year
- MSGY N/A
- CHRS $109.48
- P/E Ratio
- MSGY $28.62
- CHRS $1.05
- Revenue Growth
- MSGY 13.04
- CHRS 52.33
- 52 Week Low
- MSGY $2.33
- CHRS $0.66
- 52 Week High
- MSGY $22.20
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- MSGY N/A
- CHRS 64.41
- Support Level
- MSGY N/A
- CHRS $1.56
- Resistance Level
- MSGY N/A
- CHRS $1.72
- Average True Range (ATR)
- MSGY 0.00
- CHRS 0.12
- MACD
- MSGY 0.00
- CHRS 0.00
- Stochastic Oscillator
- MSGY 0.00
- CHRS 82.96
About MSGY Masonglory Limited Ordinary Shares
Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.